GlassScriptPhysician profile
Anthony R Ricottone
NPI 1134114051
$7,125.98
in general payments reported to CMS, 2019-2025
48 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $688 · 2021: $1,032 · 2022: $1,338 · 2023: $1,106 · 2024: $933 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,186.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $821.99 | 2019-2025 | Myrbetriq, Xtandi |
| Abbvie INC. | $798.08 | 2019-2025 | |
| Pfizer INC. | $788.14 | 2019-2025 | |
| Janssen Biotech, INC. | $575.46 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $445.09 | 2023-2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $380.03 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Tolmar Pharmaceuticals, INC. | $333.09 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $294.23 | 2019-2025 | Adstiladrin |
| Dendreon Pharmaceuticals LLC | $257.30 | 2019-2024 | Provenge |
| Caldera Medical, INC | $205.39 | 2021-2023 | Desara |
| Urogen Pharma, INC. | $186.96 | 2021-2024 | Jelmyto |
| Endo Pharmaceuticals INC. | $177.50 | 2019-2023 | Edex, Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $134.58 | 2020-2023 | Lynparza |
| Accord Healthcare, INC. | $126.15 | 2022-2025 | |
| Coloplast Corp | $112.27 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ricottone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.